Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study’ and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid”

2019 ◽  
Vol 80 (6) ◽  
pp. e191-e192
Author(s):  
Outi Varpuluoma ◽  
Kaisa Tasanen ◽  
Laura Huilaja
Keyword(s):  
Case Report ◽  
Bullous Pemphigoid ◽  
Receptor Agonist ◽  
Case Control Study ◽  
Case Control ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Control Study

scholarly journals Exposure to dipeptidyl‐peptidase‐4 inhibitors and COVID ‐19 among people with type 2 diabetes: A case‐control study

2020 ◽  
Vol 22 (10) ◽  
pp. 1946-1950 ◽  
Author(s):  
Gian Paolo Fadini ◽  
Mario Luca Morieri ◽  
Enrico Longato ◽  
Benedetta Maria Bonora ◽  
Silvia Pinelli ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Case Control Study ◽  
Dipeptidyl Peptidase ◽  
Case Control ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Control Study

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study

2016 ◽  
Vol 31 (9) ◽  
pp. 1422-1423 ◽  
Author(s):  
Per Svenningsson ◽  
Karin Wirdefeldt ◽  
Li Yin ◽  
Fang Fang ◽  
Ioanna Markaki ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Control Study ◽  
Dipeptidyl Peptidase ◽  
Case Control ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document